HSA | FSA CARDS ARE NOW ACCEPTED

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

"Compounded" Semaglutide refers to formulations of the active ingredient produced by licensed 503A compounding pharmacies — distinct from FDA-approved brand products. This article covers what compounding pharmacies can legally do, what changed in the FDA shortage resolutions of 2024–2025, how compounded products compare to brand products, and where common compounded variations (including semaglutide + B12 and microdose formulations) fit in.

What a 503A compounding pharmacy can legally do

503A pharmacies are state-licensed compounders that produce patient-specific prescriptions under a valid prescriber order. Federal law allows them to compound medications in three general categories: (1) products not commercially available, (2) products on the FDA drug shortage list, and (3) patient-specific formulations (different strength, different combination, different vehicle) that are medically necessary for an individual patient. State pharmacy boards and the FDA maintain oversight.

What the 2024–2025 shortage resolutions changed

The FDA declared semaglutide in shortage in 2022 and tirzepatide in shortage in 2022. During those shortage declarations, 503A pharmacies could compound these molecules under the second pathway above. The FDA resolved the semaglutide shortage in late 2024 and the tirzepatide shortage in early 2025, which narrowed — but did not close — the legitimate compounding window. Compounded semaglutide and tirzepatide remain available through the first and third pathways (patient-specific variations, unavailable combinations) where clinically justified.

How compounded products compare to brand products

Compounded products are legally and factually different from FDA-approved brand products. They are not subject to the same FDA manufacturing review, have their own pharmacy-specific quality processes, and may contain different vehicles, strengths, or combinations. Quality varies by pharmacy — verify state licensure and, where possible, third-party testing. Compounded products are not "generics" in any regulatory sense.

Common compounded variations

Semaglutide + cyanocobalamin (vitamin B12) combinations are common — the B12 can reduce injection-site irritation for some patients and may support energy and neurological health in B12-deficient patients. "Microdose" formulations deliver lower doses than standard titration schedules, sometimes targeting patients who experience significant GI side effects at label-directed doses. Specific strength combinations are patient-specific per the prescriber order. PlexusDx offers a Microdose GLP-1 Protocol as one of its Weight Management Protocols.

Safety considerations

Verify the compounding pharmacy is licensed in your state. Confirm the prescribing provider conducts a clinical evaluation and reviews contraindications. Be wary of vendors that ship without prescriptions, accept only cryptocurrency, or market "research chemical" products. Compounded products should include patient-specific labeling, lot numbers, beyond-use dates, and storage instructions per USP <797> (nonsterile) or USP <797>/<800> (sterile) standards.

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — available as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. What sets the PlexusDx approach apart is the upstream genetic context. Before starting any GLP-1 pathway protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, and 150+ genetic insights — including variants in FTO, GLP1R, MC4R that shape your baseline GLP-1, appetite-regulation, and energy-balance biology. Knowing that genetic profile alongside the protocol itself is the test before you invest approach — turning guesswork into an informed conversation with your healthcare provider.

Disclaimer: This article is educational. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — this article covers the mechanism, evidence, and genetic context that informs any decision to use them. PlexusDx does not sell, prescribe, or recommend any other therapeutic peptide in the GLP-1 category beyond semaglutide and tirzepatide (including dulaglutide, liraglutide, retatrutide, cagrilintide, and related compounds). The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways — it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Start with the biology. Take the Precision Peptide Genetic Test, or explore the Weight Management Protocols.

Frequently Asked Questions

What is compounded Semaglutide?

Compounded Semaglutide is a formulation of the active ingredient produced by a licensed 503A compounding pharmacy under a valid prescriber order. It is legally and factually different from the FDA-approved brand product. Strengths, vehicles, and combinations can be patient-specific. Verify state licensure and clinical evaluation before use.

Is compounded Semaglutide the same as the brand?

No. Compounded products are not subject to the same FDA manufacturing review as brand products and may differ in strength, vehicle, combinations, and quality controls. They are not "generics." Quality varies by pharmacy. PlexusDx Weight Management Protocols work with licensed compounding pathways and publish per-protocol pricing.

Why do some compounded formulations include B12?

Cyanocobalamin (vitamin B12) is sometimes included in compounded GLP-1 formulations because it can reduce injection-site discomfort for some patients and may support patients who are B12-deficient. It is a patient-specific formulation choice made by the prescribing provider — not a universal addition.

Does genetic testing predict response to compounded Semaglutide?

No. The Precision Peptide Genetic Test does not predict response to compounded semaglutide, tirzepatide, or any specific compound or formulation. It analyzes pathway-level variants in FTO, GLP1R, MC4R, and TCF7L2 that shape baseline GLP-1 and energy-balance biology — the upstream context that applies to every GLP-1 protocol.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education